학술논문
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
Document Type
Article
Author
Source
Subject
*RED blood cell transfusion
*MYELODYSPLASTIC syndromes
*ADVERSE health care events
*NAUSEA
*NEUTROPENIA
*FATIGUE (Physiology)
*THROMBOCYTOPENIA
*PATIENTS
*
*
*
*
*
*
*
Language
ISSN
0887-6924
Abstract
The article presents clinical trial which examined the activity of orallly administered panobinostat (LBH589) in red blood cell (RBC) transfusion-dependent patients with myelodysplastic syndromes (MDS). The most frequently reported adverse events (AEs) were nausea, neutropenia, fatigue, thrombocytopenia and diarrhea. It showed that 38% of patients experienced AEs which suggests that caution is suggested particularly in elderly patients who underwent LBH589 treatment in clinical trials.